

Drug Monograph

Drug/Drug **LATUDA[®] (lurasidone hydrochloride) 120 mg Tablet/**

Class: **Atypical Antipsychotic**

Prepared for: MO HealthNet

Prepared by: Xerox Heritage LLC

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Each tablet of Latuda [®] contains 120 mg of lurasidone hydrochloride.
Manufacturer:	Sunovion Pharmaceuticals Inc. Marlborough, MA 01752
Indications:	Latuda is indicated for the treatment of patients with schizophrenia.
Costs:	\$ 26.83 per tablet of Latuda Wholesale Acquisition Cost
Summary of Findings:	MO HealthNet Division recommends this product be added to the 15 Day First Fill Fiscal Edit and the Atypical Antipsychotic Clinical Edit.
Status Recommendation:	<input type="checkbox"/> Prior Authorization (PA) Required <input type="checkbox"/> Open Access <input checked="" type="checkbox"/> Clinical Edit <input type="checkbox"/> PDL
Type of PA Criteria:	<input type="checkbox"/> Increased Risk of ADE <input type="checkbox"/> Preferred Agent <input checked="" type="checkbox"/> Appropriate Indications <input type="checkbox"/> No PA Required

Prepared By: Ami Patel, Pharm. D. Candidate
Date: October 17th 2012